Relmada Therapeutics to Present at Jefferies London Healthcare Conference [Yahoo! Finance]
Relmada Therapeutics, Inc. (RLMD)
NASDAQ:AMEX Investor Relations:
ir.relmada.com
Company Research
Source: Yahoo! Finance
Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Jefferies London Healthcare Conference details Presentation: Wednesday, November 20, 2024 at 12:00 PM GMT Speaker: Sergio Traversa, CEO Registration: Webcast link The replay of the webcast will be available on the “For Investors/Events” page of the Relmada website for 90 days following the conference. About Relmada Therapeutics, Inc. Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NM
Show less
Read more
Impact Snapshot
Event Time:
RLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLMD alerts
High impacting Relmada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLMD
News
- Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmGlobeNewswire
- Relmada Therapeutics to Present at Jefferies London Healthcare ConferenceGlobeNewswire
- Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]Yahoo! Finance
- Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseGlobeNewswire
- Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... [Yahoo! Finance]Yahoo! Finance
RLMD
Earnings
- 11/7/24 - Miss
RLMD
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 10/23/24 - Form 4
- RLMD's page on the SEC website